Literature DB >> 6141645

Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents.

W P Boger.   

Abstract

The dissipation phenomena associated with timolol have important implications in the clinical management of glaucoma patients. Shortterm "escape" and longterm "drift" are clinical terms which describe the reduction of timolol's efficacy over a few days and over months and years, respectively. Recent physiological studies suggest a cellular explanation for these readjustments in tissue responsiveness to continued administration of timolol. While the precise location of the physiologically responding cells and the interactions of the various adrenergic responsive elements remain unclear, subsensitivity and supersensitivity may prove to be the most accurate designations for alterations in tissue responsiveness to adrenergic stimulation following "down regulation" or "up regulation" of beta receptor density on cell membranes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141645     DOI: 10.1016/0039-6257(83)90138-8

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  8 in total

Review 1.  New developments in the drug treatment of glaucoma.

Authors:  L M Hurvitz; P L Kaufman; A L Robin; R N Weinreb; K Crawford; B Shaw
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

2.  Long-term drift and timolol therapy: possible role for pulsed therapy.

Authors:  M Batterbury; S P Harding; D Wong
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

Review 3.  Pharmacological management of primary open-angle glaucoma: second-line options and beyond.

Authors:  Carroll A B Webers; Henny J M Beckers; Rudy M M A Nuijts; Jan S A G Schouten
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination.

Authors:  Kenji Inoue; Ryoko Okayama; Risako Higa; Masato Wakakura; Goji Tomita
Journal:  Clin Ophthalmol       Date:  2012-04-18

6.  Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial.

Authors:  Jerry Tsai; Anna L Chien; Noori Kim; Saleh Rachidi; Brian M Connolly; Hester Lim; Sabrina Sisto Alessi César; Sewon Kang; Luis A Garza
Journal:  J Am Acad Dermatol       Date:  2021-02-03       Impact factor: 15.487

7.  Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon.

Authors:  Jie Shen; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2016-03-03

Review 8.  Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension.

Authors:  Sourabh Sharma; Sameer Trikha; Shamira A Perera; Tin Aung
Journal:  Clin Ophthalmol       Date:  2015-11-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.